Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
MBX Biosciences, Inc. MBX

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Oct 22, 2026 8-K 2 signals fired
Other
Audit Committee Independence Certification Classified Board Director Election
Aug 27, 2026 8-K 16 signals fired · top 15
Core
Regulatory Designation Only Secondary Endpoint Mentioned Clinical Trial Result Indication Expansion Lead Asset Progress Clinical Hold Combination Therapy Mentioned
Other
Fast Track Designation Received Interim Data Positive Fast Track Granted Enrollment Ahead Of Schedule Kol Endorsement Protocol Amended Fda Aligned
Biotech Risk
Orphan Drug Designation
Jul 13, 2026 8-K 2 signals fired
Other
Rsu Psu Vesting Schedule Disclosed
Core
Management Exodus
Jun 12, 2026 8-K 17 signals fired · top 15
Other
Patient Retention High Interim Data Positive Kol Endorsement Fda Aligned Publication Positive Enrollment Ahead Of Schedule Expanded Access Program Active Fast Track Granted
Core
Clinical Trial Result Secondary Endpoint Mentioned Indication Expansion Lead Asset Progress Combination Therapy Mentioned Clinical Hold
Biotech v3
Ai Drug Discovery Investment
Jun 5, 2026 8-K 2 signals fired
Other
Auditor Appointment Ratification Classified Board Director Election
May 11, 2026 8-K 17 signals fired · top 15
Core
Clinical Trial Result Indication Expansion Lead Asset Progress Combination Therapy Mentioned Clinical Hold Secondary Endpoint Mentioned
Other
Patient Retention High Kol Endorsement Interim Data Positive Safety Differentiated Fda Aligned Publication Positive Expanded Access Program Active Enrollment Ahead Of Schedule
Biotech v3
Ind Submission Planned
May 7, 2026 10-Q 40 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Ip Assignment To Company Codm Segment Reporting Disclosure Net Loss Reported Cash Flow Statement Investing Activities Ipo Or Capital Raising Completion Ipo Net Proceeds Disclosure Operating Lease Rent Expense Disclosed Financing Activities Cash Flow Disclosure Equity Plan Share Reserve Disclosure Interim Data Positive Liquidity Position Snapshot Disclosed Amendment Modification Waiver Clause Survival Of Representations Warranties Clause
Core
Clinical Trial Result
May 7, 2026 8-K 14 signals fired
Other
Net Loss Reported Liquidity Position Snapshot Disclosed Expanded Access Program Active Interim Data Positive Kol Endorsement Geographic Footprint Disclosure Enrollment Ahead Of Schedule Publication Positive
Core
Clinical Trial Result Indication Expansion Lead Asset Progress Clinical Hold
Biotech v3
Ai Drug Discovery Investment
Biotech Risk
Clinical Hold Active